Retrospective mathematical analysis of serial prostate specific antigen (PSA) measurements for patients with M0 prostate cancer treated with intermittent androgen suppression (IAS)

被引：0
|
作者：
Higano, Celestia S.
Hirata, Yoshito
Akakura, Koichiro
Bruchovsky, Nicholas
Aihara, Kazuyuki
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Univ Tokyo, Inst Ind Sci, Tokyo, Japan
[3] Tokyo Koseinenkin Hosp, Dept Urol, Tokyo, Japan
[4] Vancouver Prostate Ctr, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15201
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression
    Hirata, Yoshito
    Akakura, Koichiro
    Higano, Celestia S.
    Bruchovsky, Nicholas
    Aihara, Kazuyuki
    [J]. JOURNAL OF MOLECULAR CELL BIOLOGY, 2012, 4 (03) : 127 - 132
  • [2] Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy
    Theyer, G
    Holub, S
    Durer, A
    Andert, S
    Haberl, I
    Theyer, U
    Hamilton, G
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (10) : 1515 - 1518
  • [3] Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy
    G Theyer
    S Holub
    A Dürer
    S Andert
    I Haberl
    U Theyer
    G Hamilton
    [J]. British Journal of Cancer, 1997, 75 : 1515 - 1518
  • [4] Phase II study of intermittent androgen suppression (IAS) in prostate cancer patients.
    Bracarda, S
    Rosi, P
    De Angelis, V
    Mearini, E
    Porena, M
    Tonato, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 31 - 31
  • [5] PSA doubling time (PSA-DT) during the "off treatment" interval in men with biochemical relapse of prostate cancer treated with intermittent androgen suppression (IAS)
    Howlander, N
    Tam, S
    Etzioni, R
    Higano, CS
    Hutchinson, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 420S - 420S
  • [6] Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients
    Oliver, RTD
    Lee, A
    Farrugia, D
    Ansell, W
    [J]. BRITISH JOURNAL OF CANCER, 2001, 85 : 88 - 88
  • [7] Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients
    Oliver, RTD
    Farrugia, D
    Ansell, W
    Willams, G
    Chinegwundoh, F
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2000, 3 (04) : 286 - 289
  • [8] Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients
    RTD Oliver
    D Farrugia
    W Ansell
    G Williams
    F Chinegwundoh
    [J]. Prostate Cancer and Prostatic Diseases, 2000, 3 : 286 - 289
  • [9] Mathematical Models of Androgen Resistance in Prostate Cancer Patients under Intermittent Androgen Suppression Therapy
    Baez, Javier
    Kuang, Yang
    [J]. APPLIED SCIENCES-BASEL, 2016, 6 (11):
  • [10] Prostate specific antigen monitoring value in patients with advanced prostate cancer submitted to androgen suppression
    Jora, T.
    Geavlete, P.
    [J]. ACTA ENDOCRINOLOGICA-BUCHAREST, 2007, 3 (03) : 303 - 314
12345